Latest news with #COVID-19Vaccine
Business Wire
16-07-2025
- Business
- Business Wire
Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2025. 'Today's strong results reflect the depth and strength of Johnson & Johnson's uniquely diversified business operating across both MedTech and Innovative Medicine,' said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. 'Our portfolio and pipeline position us for elevated growth in the second half of the year, with game-changing approvals and submissions anticipated in areas like lung and bladder cancer, major depressive disorder, psoriasis, surgery and cardiovascular, which will extend and improve lives in transformative ways.' Overall financial results 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Excludes intangible amortization expense and special items 5 Excludes COVID-19 Vaccine 6 Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings. 7 Second-quarter YTD 2025 is estimated as of July 16, 2025 Note: values may have been rounded Expand Regional sales results 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: values may have been rounded Expand Segment sales results 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: values may have been rounded Expand Second-Quarter 2025 segment commentary: Operational sales* reflected below excludes the impact of translational currency. Innovative Medicine Innovative Medicine worldwide operational sales grew 3.8%*, with net acquisitions and divestitures positively impacting growth by 1.4%. Growth was primarily driven by DARZALEX, CARVYKTI, ERLEADA and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SPRAVATO in Neuroscience. Growth was partially offset by an approximate (1,170) basis points impact from STELARA in Immunology, and an approximate (130) basis points impact from COVID-19 in Infectious Diseases. MedTech MedTech worldwide operational sales grew 6.1%*, with net acquisitions and divestitures positively impacting growth by 2.0%. Growth was primarily driven by electrophysiology products and Abiomed in Cardiovascular, as well as wound closure products in General Surgery. Full-year 2025 guidance: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP. 1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures 2 Non-GAAP financial measure; excludes the impact of translational currency 3 Calculated using Euro Average Rate: July 2025 = $1.13 and April 2025 = $1.10 (Illustrative purposes only) 4 Non-GAAP financial measure; excludes intangible amortization expense and special items 5 Excludes COVID-19 Vaccine Note: percentages may have been rounded Expand Other modeling considerations will be provided on the webcast Notable announcements in the quarter: The information contained in this section should be read together with Johnson & Johnson's other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company's website at News Releases, as well as Innovative Medicine News Center, MedTech News & Events, and Webcast information: Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations. About Johnson & Johnson: At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at Non-GAAP financial measures: * 'Operational sales growth' excluding the impact of translational currency, 'adjusted operational sales growth' excluding the net impact of acquisitions and divestitures and translational currency, as well as 'adjusted net earnings', 'adjusted diluted earnings per share' and 'adjusted operational diluted earnings per share' excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results. Copies of the financial schedules accompanying this earnings release are available on the company's website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results. Note to investors concerning forward-looking statements: This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; and increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) SECOND QUARTER Sales to customers by geographic area U.S. $ 13,544 12,569 7.8 % 7.8 - $ 25,849 24,189 6.9 % 6.9 - Europe 5,387 5,214 3.3 (1.9 ) 5.2 10,497 10,377 1.1 0.2 0.9 Western Hemisphere excluding U.S. 1,206 1,212 (0.5 ) 6.2 (6.7 ) 2,373 2,406 (1.3 ) 7.7 (9.0 ) Asia-Pacific, Africa 3,606 3,452 4.4 2.4 2.0 6,917 6,858 0.9 0.9 0.0 International 10,199 9,878 3.2 0.6 2.6 19,787 19,641 0.7 1.4 (0.7 ) Worldwide $ 23,743 22,447 5.8 % 4.6 1.2 $ 45,636 43,830 4.1 % 4.4 (0.3 ) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. Expand Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) SIX MONTHS 2025 2024 Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers $ 45,636 100.0 $ 43,830 100.0 4.1 Cost of products sold 14,985 32.8 13,380 30.5 12.0 Gross Profit 30,651 67.2 30,450 69.5 0.7 Selling, marketing and administrative expenses 11,001 24.1 10,938 25.0 0.6 Research and development expense 6,741 14.8 6,982 16.0 (3.5 ) In-process research and development impairments - - 194 0.4 Interest (income) expense, net (80 ) (0.2 ) (334 ) (0.8 ) Other (income) expense, net (7,214 ) (15.8 ) 3,057 7.0 Restructuring 81 0.2 151 0.3 Earnings before provision for taxes on income 20,122 44.1 9,462 21.6 112.7 Provision for taxes on income 3,586 7.9 1,521 3.5 135.8 Net earnings $ 16,536 36.2 $ 7,941 18.1 108.2 Net earnings per share (Diluted) $ 6.82 $ 3.27 108.6 Average shares outstanding (Diluted) 2,423.3 2,428.5 Effective tax rate 17.8 % 16.1 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income $ 16,199 35.5 $ 16,281 37.1 (0.5 ) Net earnings $ 13,405 29.4 $ 13,420 30.6 (0.1 ) Net earnings per share (Diluted) $ 5.53 $ 5.53 0.0 Effective tax rate 17.2 % 17.6 % (1) See Reconciliation of Non-GAAP Financial Measures. Expand Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures Second Quarter Six Months Ended (Dollars in Millions Except Per Share Data) 2025 2024 2025 2024 Net Earnings, after tax- as reported $5,537 $4,686 $16,536 $7,941 Pre-tax Adjustments Litigation related 57 352 (6,909) 3,078 Intangible Asset Amortization expense 1,267 1,106 2,387 2,184 COVID-19 Vaccine related costs - 64 - 73 Restructuring related 1 79 (11) 134 160 Medical Device Regulation - 68 - 119 Acquisition, integration and divestiture related 246 452 378 600 (Gains)/losses on securities 21 431 60 411 IPR&D impairments - 194 - 194 Other 27 - 27 - Tax Adjustments Tax impact on special item adjustments 2 (321) (437) 994 (1,293) Tax legislation and other tax related (214) (65) (202) (47) Adjusted Net Earnings , after tax $6,699 $6,840 $13,405 $13,420 Average shares outstanding (Diluted) 2,419.1 2,422.0 2,423.3 2,428.5 Adjusted net earnings per share (Diluted) $2.77 $2.82 $5.53 $5.53 Operational adjusted net earnings per share (Diluted) $2.71 $5.52 Notes: 1 In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits were primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring income of $63 million in the fiscal second quarter of 2024 ($81 million expense Q2 2024 YTD) included asset divestments and the termination of partnered and non-partnered program costs and asset impairments. This program was completed in Q4 2024. In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $50 million in the fiscal second quarter of 2025 ($105 million Q2 2025 YTD) and $52 million in the fiscal second quarter of 2024 ($79 million Q2 2024 YTD) includes costs related to market and product exits. In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. Restructuring expenses of $29 million were recorded in the fiscal second quarter of 2025. 2 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. Expand REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) % Change % Change ONCOLOGY US $ 3,385 2,636 28.4 % 28.4 % - $ 6,398 5,019 27.5 % 27.5 % - Intl 2,928 2,455 19.3 % 15.7 % 3.6 % 5,592 4,885 14.5 % 15.1 % -0.6 % WW 6,312 5,090 24.0 % 22.3 % 1.7 % 11,990 9,904 21.1 % 21.3 % -0.2 % CARVYKTI US 358 167 * * - 676 307 * * - Intl 81 20 * * * 132 36 * * * WW 439 186 * * * 808 343 * * * DARZALEX US 2,017 1,641 23.0 % 23.0 % - 3,846 3,105 23.9 % 23.9 % - Intl 1,521 1,237 23.0 % 19.6 % 3.4 % 2,930 2,465 18.9 % 19.7 % -0.8 % WW 3,539 2,878 23.0 % 21.5 % 1.5 % 6,776 5,570 21.7 % 22.0 % -0.3 % ERLEADA US 378 318 18.6 % 18.6 % - 670 603 11.0 % 11.0 % - Intl 530 418 27.0 % 22.8 % 4.2 % 1,009 822 22.9 % 23.0 % -0.1 % WW 908 736 23.4 % 21.0 % 2.4 % 1,679 1,425 17.8 % 17.9 % -0.1 % IMBRUVICA US 239 246 -2.7 % -2.7 % - 474 511 -7.3 % -7.3 % - Intl 496 525 -5.4 % -8.4 % 3.0 % 970 1,043 -6.9 % -6.3 % -0.6 % WW 735 770 -4.5 % -6.6 % 2.1 % 1,444 1,554 -7.0 % -6.6 % -0.4 % RYBREVANT / LAZCLUZE (3) US 139 52 * * - 252 88 * * - Intl 41 17 * * * 69 28 * * * WW 179 69 * * * 320 116 * * * TALVEY US 82 59 38.0 % 38.0 % - 150 109 36.7 % 36.7 % - Intl 24 9 * * * 42 17 * * * WW 106 69 55.0 % 54.3 % 0.7 % 192 127 52.0 % 52.4 % -0.4 % TECVAYLI US 114 104 8.2 % 8.2 % - 219 205 6.6 % 6.6 % - Intl 52 30 74.8 % 72.0 % 2.8 % 98 63 56.0 % 58.4 % -2.4 % WW 166 135 23.1 % 22.4 % 0.7 % 317 268 18.2 % 18.7 % -0.5 % ZYTIGA / abiraterone acetate US 6 11 -38.9 % -38.9 % - 13 20 -31.9 % -31.9 % - Intl 139 154 -9.8 % -13.3 % 3.5 % 257 326 -21.1 % -21.3 % 0.2 % WW 145 165 -11.6 % -14.9 % 3.3 % 270 346 -21.7 % -21.9 % 0.2 % OTHER ONCOLOGY US 50 37 36.9 % 36.9 % - 97 70 39.8 % 39.8 % - Intl 42 45 -8.7 % -12.3 % 3.6 % 84 86 -2.5 % -1.8 % -0.7 % WW 93 83 11.7 % 9.7 % 2.0 % 182 156 16.4 % 16.8 % -0.4 % See footnotes at end of schedule REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS % Change % Change IMMUNOLOGY US $ 2,505 2,978 -15.9 % -15.9 % - $ 4,701 5,431 -13.4 % -13.4 % - Intl 1,489 1,744 -14.6 % -16.2 % 1.6 % 2,999 3,538 -15.2 % -13.8 % -1.4 % WW 3,993 4,722 -15.4 % -16.0 % 0.6 % 7,700 8,969 -14.1 % -13.6 % -0.5 % REMICADE US 283 231 22.5 % 22.5 % - 597 497 20.1 % 20.1 % - US Exports (4) 34 35 -2.6 % -2.6 % - 44 62 -28.7 % -28.7 % - Intl 138 127 8.6 % 8.8 % -0.2 % 281 268 4.8 % 7.7 % -2.9 % WW 455 393 15.9 % 15.9 % 0.0 % 922 827 11.5 % 12.4 % -0.9 % SIMPONI / SIMPONI ARIA US 305 267 14.0 % 14.0 % - 597 521 14.4 % 14.4 % - Intl 387 270 43.1 % 40.8 % 2.3 % 753 569 32.2 % 35.0 % -2.8 % WW 690 537 28.6 % 27.5 % 1.1 % 1,349 1,091 23.7 % 25.1 % -1.4 % STELARA US 1,078 1,855 -41.9 % -41.9 % - 2,059 3,251 -36.7 % -36.7 % - Intl 575 1,030 -44.2 % -45.6 % 1.4 % 1,219 2,085 -41.5 % -40.6 % -0.9 % WW 1,653 2,885 -42.7 % -43.2 % 0.5 % 3,278 5,336 -38.6 % -38.2 % -0.4 % TREMFYA US 796 589 35.2 % 35.2 % - 1,395 1,098 27.1 % 27.1 % - Intl 391 317 23.2 % 20.5 % 2.7 % 747 616 21.2 % 22.4 % -1.2 % WW 1,186 906 31.0 % 30.1 % 0.9 % 2,142 1,714 25.0 % 25.4 % -0.4 % OTHER IMMUNOLOGY US 8 2 * * - 9 2 * * - Intl 0 0 - - - 0 0 - - - WW 8 2 * * - 9 2 * * - NEUROSCIENCE US 1,377 1,102 24.9 % 24.9 % - 2,345 2,156 8.7 % 8.7 % - Intl 674 679 -0.8 % -2.6 % 1.8 % 1,353 1,428 -5.2 % -4.1 % -1.1 % WW 2,051 1,782 15.1 % 14.4 % 0.7 % 3,698 3,585 3.2 % 3.6 % -0.4 % CAPLYTA (5) US 211 - * * - 211 - * * - Intl - - - - - - - - - - WW 211 - * * - 211 - * * - CONCERTA / Methylphenidate US 24 34 -27.7 % -27.7 % - 62 75 -16.6 % -16.6 % - Intl 139 129 7.5 % 7.0 % 0.5 % 249 265 -6.0 % -4.4 % -1.6 % WW 164 163 0.2 % -0.2 % 0.4 % 312 340 -8.3 % -7.1 % -1.2 % INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 732 784 -6.7 % -6.7 % - 1,357 1,549 -12.4 % -12.4 % - Intl 260 269 -3.5 % -5.1 % 1.6 % 537 561 -4.2 % -3.1 % -1.1 % WW 992 1,054 -5.9 % -6.3 % 0.4 % 1,895 2,110 -10.2 % -9.9 % -0.3 % SPRAVATO US 366 226 61.1 % 61.1 % - 642 417 53.7 % 53.7 % - Intl 50 44 12.8 % 11.0 % 1.8 % 93 78 18.1 % 20.1 % -2.0 % WW 414 271 53.3 % 53.0 % 0.3 % 734 496 48.1 % 48.4 % -0.3 % OTHER NEUROSCIENCE US 45 57 -23.5 % -23.5 % - 73 115 -37.0 % -37.0 % - Intl 226 237 -4.7 % -7.6 % 2.9 % 474 524 -9.5 % -8.8 % -0.7 % WW 270 294 -8.4 % -10.7 % 2.3 % 547 639 -14.4 % -13.9 % -0.5 % See footnotes at end of schedule REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS % Change % Change PULMONARY HYPERTENSION US $ 799 743 7.6 % 7.6 % - $ 1,543 1,509 2.3 % 2.3 % - Intl 314 296 5.8 % 2.8 % 3.0 % 595 579 2.6 % 3.0 % -0.4 % WW 1,113 1,039 7.1 % 6.2 % 0.9 % 2,138 2,088 2.4 % 2.5 % -0.1 % OPSUMIT / OPSYNVI US 403 376 6.9 % 6.9 % - 766 732 4.6 % 4.6 % - Intl 180 171 5.4 % 2.1 % 3.3 % 339 340 -0.3 % -0.2 % -0.1 % WW 582 548 6.4 % 5.4 % 1.0 % 1,104 1,072 3.0 % 3.1 % -0.1 % UPTRAVI US 382 349 9.4 % 9.4 % - 747 741 0.8 % 0.8 % - Intl 94 76 22.4 % 19.8 % 2.6 % 180 152 17.9 % 18.7 % -0.8 % WW 476 426 11.7 % 11.3 % 0.4 % 927 894 3.7 % 3.8 % -0.1 % OTHER PULMONARY HYPERTENSION US 16 17 -12.4 % -12.4 % - 31 35 -12.6 % -12.6 % - Intl 40 49 -18.5 % -21.3 % 2.8 % 77 88 -12.4 % -12.1 % -0.3 % WW 55 67 -16.9 % -19.0 % 2.1 % 107 123 -12.5 % -12.3 % -0.2 % INFECTIOUS DISEASES US 320 334 -4.3 % -4.3 % - 635 658 -3.6 % -3.6 % - Intl 484 631 -23.4 % -26.8 % 3.4 % 971 1,128 -13.9 % -14.1 % 0.2 % WW 803 965 -16.8 % -19.0 % 2.2 % 1,605 1,786 -10.1 % -10.2 % 0.1 % EDURANT / rilpivirine US 6 8 -25.4 % -25.4 % - 14 16 -13.6 % -13.6 % - Intl 354 288 23.0 % 16.7 % 6.3 % 704 603 16.7 % 15.6 % 1.1 % WW 360 297 21.6 % 15.5 % 6.1 % 718 620 15.9 % 14.9 % 1.0 % PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 312 321 -3.0 % -3.0 % - 617 635 -2.9 % -2.9 % - Intl 85 117 -27.0 % -29.4 % 2.4 % 183 221 -17.2 % -15.8 % -1.4 % WW 396 438 -9.4 % -10.0 % 0.6 % 799 856 -6.6 % -6.3 % -0.3 % OTHER INFECTIOUS DISEASES US 2 5 -51.8 % -51.8 % - 4 7 -37.4 % -37.4 % - Intl 45 227 -80.5 % -80.6 % 0.1 % 84 304 -72.5 % -72.1 % -0.4 % WW 47 233 -79.8 % -79.9 % 0.1 % 88 311 -71.7 % -71.3 % -0.4 % CARDIOVASCULAR / METABOLISM / OTHER US 776 717 8.2 % 8.2 % - 1,631 1,348 21.0 % 21.0 % - Intl 154 176 -12.3 % -13.2 % 0.9 % 312 373 -16.2 % -14.3 % -1.9 % WW 930 892 4.2 % 4.0 % 0.2 % 1,943 1,721 12.9 % 13.3 % -0.4 % XARELTO US 621 587 5.6 % 5.6 % - 1,311 1,105 18.6 % 18.6 % - Intl - - - - - - - - - - WW 621 587 5.6 % 5.6 % - 1,311 1,105 18.6 % 18.6 % - OTHER US 155 129 20.0 % 20.0 % - 320 243 31.6 % 31.6 % - Intl 154 176 -12.3 % -13.2 % 0.9 % 312 373 -16.2 % -14.3 % -1.9 % WW 309 305 1.4 % 0.9 % 0.5 % 632 616 2.7 % 3.9 % -1.2 % TOTAL INNOVATIVE MEDICINE US 9,161 8,510 7.6 % 7.6 % - 17,253 16,122 7.0 % 7.0 % - Intl 6,041 5,980 1.0 % -1.6 % 2.6 % 11,822 11,930 -0.9 % -0.1 % -0.8 % WW $ 15,202 14,490 4.9 % 3.8 % 1.1 % $ 29,075 28,052 3.6 % 4.0 % -0.4 % See footnotes at end of schedule REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS % Change % Change CARDIOVASCULAR US $ 1,364 1,119 21.9 % 21.9 % - $ 2,625 2,144 22.4 % 22.4 % - Intl 948 753 25.9 % 22.9 % 3.0 % 1,790 1,534 16.7 % 16.7 % 0.0 % WW 2,313 1,873 23.5 % 22.3 % 1.2 % 4,416 3,679 20.0 % 20.0 % 0.0 % ELECTROPHYSIOLOGY US 741 705 5.1 % 5.1 % - 1,425 1,397 2.0 % 2.0 % - Intl 728 618 17.8 % 15.2 % 2.6 % 1,366 1,270 7.6 % 7.8 % -0.2 % WW 1,468 1,323 11.0 % 9.8 % 1.2 % 2,791 2,667 4.7 % 4.7 % 0.0 % ABIOMED US 360 309 16.6 % 16.6 % - 699 612 14.2 % 14.2 % - Intl 89 72 25.0 % 18.4 % 6.6 % 170 139 22.4 % 20.9 % 1.5 % WW 448 379 18.2 % 16.9 % 1.3 % 868 750 15.7 % 15.5 % 0.2 % SHOCKWAVE (6) US 233 77 * * - 439 77 * * - Intl 58 0 * * * 110 0 * * * WW 292 77 * * * 550 77 * * - OTHER CARDIOVASCULAR US 31 29 5.4 % 5.4 % - 63 59 6.3 % 6.3 % - Intl 72 64 13.4 % 11.6 % 1.8 % 144 126 14.2 % 14.5 % -0.3 % WW 104 93 10.8 % 9.7 % 1.1 % 207 185 11.7 % 11.8 % -0.1 % ORTHOPAEDICS US 1,420 1,422 -0.2 % -0.2 % - 2,804 2,870 -2.3 % -2.3 % - Intl 885 890 -0.5 % -4.0 % 3.5 % 1,742 1,782 -2.2 % -2.4 % 0.2 % WW 2,305 2,312 -0.3 % -1.6 % 1.3 % 4,546 4,652 -2.3 % -2.3 % 0.0 % HIPS US 271 265 2.1 % 2.1 % - 534 535 -0.2 % -0.2 % - Intl 150 152 -1.0 % -4.3 % 3.3 % 296 304 -2.5 % -2.6 % 0.1 % WW 421 417 1.0 % -0.2 % 1.2 % 830 839 -1.1 % -1.1 % 0.0 % KNEES US 226 230 -1.9 % -1.9 % - 457 472 -3.1 % -3.1 % - Intl 164 163 0.0 % -2.9 % 2.9 % 322 323 -0.5 % -0.4 % -0.1 % WW 389 394 -1.1 % -2.3 % 1.2 % 778 795 -2.0 % -2.0 % 0.0 % TRAUMA US 501 498 0.7 % 0.7 % - 1,003 1,002 0.1 % 0.1 % - Intl 267 260 2.2 % -1.5 % 3.7 % 537 521 2.9 % 2.8 % 0.1 % WW 768 759 1.2 % -0.1 % 1.3 % 1,540 1,524 1.1 % 1.0 % 0.1 % SPINE, SPORTS & OTHER US 422 430 -1.7 % -1.7 % - 810 862 -6.0 % -6.0 % - Intl 305 314 -2.7 % -6.4 % 3.7 % 588 634 -7.2 % -7.7 % 0.5 % WW 727 743 -2.1 % -3.7 % 1.6 % 1,398 1,495 -6.5 % -6.7 % 0.2 % See footnotes at end of schedule REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS % Change % Change SURGERY US $ 1,043 995 4.8 % 4.8 % - $ 2,045 1,982 3.2 % 3.2 % - Intl 1,512 1,493 1.3 % -0.2 % 1.5 % 2,906 2,922 -0.5 % 0.3 % -0.8 % WW 2,555 2,488 2.7 % 1.8 % 0.9 % 4,951 4,904 1.0 % 1.5 % -0.5 % ADVANCED US 477 466 2.2 % 2.2 % - 934 912 2.4 % 2.4 % - Intl 687 675 1.9 % 0.2 % 1.7 % 1,303 1,316 -1.0 % -0.4 % -0.6 % WW 1,164 1,141 2.0 % 1.0 % 1.0 % 2,237 2,228 0.4 % 0.8 % -0.4 % GENERAL US 567 528 7.2 % 7.2 % - 1,111 1,070 3.8 % 3.8 % - Intl 825 818 0.9 % -0.6 % 1.5 % 1,603 1,606 -0.1 % 0.8 % -0.9 % WW 1,391 1,346 3.3 % 2.5 % 0.8 % 2,714 2,676 1.4 % 2.0 % -0.6 % VISION US 557 523 6.5 % 6.5 % - 1,123 1,070 4.9 % 4.9 % - Intl 813 763 6.5 % 3.4 % 3.1 % 1,526 1,473 3.6 % 3.7 % -0.1 % WW 1,369 1,285 6.5 % 4.6 % 1.9 % 2,648 2,543 4.1 % 4.2 % -0.1 % CONTACT LENSES / OTHER US 429 409 4.8 % 4.8 % - 881 847 3.9 % 3.9 % - Intl 536 509 5.4 % 1.4 % 4.0 % 1,003 981 2.3 % 1.9 % 0.4 % WW 965 918 5.1 % 2.9 % 2.2 % 1,884 1,828 3.1 % 2.8 % 0.3 % SURGICAL US 128 113 12.6 % 12.6 % - 242 223 8.5 % 8.5 % - Intl 277 254 8.8 % 7.3 % 1.5 % 523 492 6.2 % 7.2 % -1.0 % WW 403 367 9.9 % 8.9 % 1.0 % 764 715 6.9 % 7.6 % -0.7 % TOTAL MEDTECH US 4,383 4,059 8.0 % 8.0 % - 8,596 8,067 6.6 % 6.6 % - Intl 4,158 3,898 6.7 % 4.1 % 2.6 % 7,965 7,711 3.3 % 3.6 % -0.3 % WW $ 8,541 7,957 7.3 % 6.1 % 1.2 % $ 16,561 15,778 5.0 % 5.1 % -0.1 % Expand Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE (4) Reported as U.S. sales (5) Acquired with Intra-Cellular Therapies on April 2, 2025 (6) Acquired on May 31, 2024 Expand
Business Insider
19-05-2025
- Health
- Business Insider
FDA approves Novavax COVID-19 vaccine with restrictions
The FDA approved Novavax's (NVAX) COVID-19 vaccine in a letter to the company dated Friday. 'Under this license, you are authorized to manufacture the product COVID-19 Vaccine, Adjuvanted, which is indicated for active immunization to prevent coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 in adults 65 years and older. Additionally, COVID-19 Vaccine, Adjuvanted is indicated for individuals 12 through 64 years who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.' The agency added, 'We did not refer your application to the Vaccines and Related Biological Products Advisory Committee because our review of information submitted in your BLA, including the clinical study design and trial results, did not raise concerns or controversial issues that would have benefited from an advisory committee discussion.' Confident Investing Starts Here:
